product summary
Loading...
company name :
Sino Biological
product type :
protein
product name :
SARS-CoV-2 (2019-nCoV) Spike S1(D614G)-His Recombinant Protein, (HPLC-verified)
catalog :
40591-V08H3
quantity :
100 µg
price :
498 USD
more info or order :
Sino Biological product webpage
citations: 18
Reference
Han B, Lv Y, Moser D, Zhou X, Woehrle T, Han L, et al. ACE2-independent SARS-CoV-2 virus entry through cell surface GRP78 on monocytes - evidence from a translational clinical and experimental approach. EBioMedicine. 2023;98:104869 pubmed publisher
Shengnan Z, Yingjie Z, Junyue C, Shuangshuang S, Xin L, Yuanyuan S. Exploring the binding effect and mechanism of glycyrrhizin to ovomucin by combining spectroscopic analysis and molecular docking. Int J Biol Macromol. 2023;245:125535 pubmed publisher
Hu R, Yang Y, Liu Y, Liao T, Liu Y, Tang J, et al. Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip. J Nanobiotechnology. 2022;20:533 pubmed publisher
Pi Estopi xf1 an F, P xe9 rez M, Fraga A, Bergado G, D xed az G, Orosa I, et al. A cell-based ELISA as surrogate of virus neutralization assay for RBD SARS-CoV-2 specific antibodies. Vaccine. 2022;40:1958-1967 pubmed publisher
Zhu F, Zhong Y, Ji H, Ge R, Guo L, Song H, et al. ACE2 and TMPRSS2 in human saliva can adsorb to the oral mucosal epithelium. J Anat. 2022;240:398-409 pubmed publisher
Puligedda R, Al Saleem F, Wirblich C, Kattala C, Jovic M, Geiszler L, et al. A Strategy to Detect Emerging Non-Delta SARS-CoV-2 Variants with a Monoclonal Antibody Specific for the N501 Spike Residue. Diagnostics (Basel). 2021;11: pubmed publisher
Caohuy H, Eidelman O, Chen T, Liu S, Yang Q, Bera A, et al. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells. Sci Rep. 2021;11:22195 pubmed publisher
Longworth J, Dittmar G. An antigen microarray protocol for COVID-19 serological analysis. STAR Protoc. 2021;2:100815 pubmed publisher
Shukla S, Cho K, Rustagi V, Gao X, Fu X, Zhang S, et al. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry. Int J Mol Sci. 2021;22: pubmed publisher
Arroyo R, Grant S, Colombo M, Salvioni L, Corsi F, Truffi M, et al. Full-Length Recombinant hSP-D Binds and Inhibits SARS-CoV-2. Biomolecules. 2021;11: pubmed publisher
Zhou Z, Dharmarajan S, Lehtimäki M, Kirshner S, Kozlowski S. Early antibody responses associated with survival in COVID19 patients. PLoS Pathog. 2021;17:e1009766 pubmed publisher
Yue J, Jin W, Yang H, Faulkner J, Song X, Qiu H, et al. Heparan Sulfate Facilitates Spike Protein-Mediated SARS-CoV-2 Host Cell Invasion and Contributes to Increased Infection of SARS-CoV-2 G614 Mutant and in Lung Cancer. Front Mol Biosci. 2021;8:649575 pubmed publisher
Cao Y, Yisimayi A, Bai Y, Huang W, Li X, Zhang Z, et al. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. Cell Res. 2021;31:732-741 pubmed publisher
Guo Y, Huang L, Zhang G, Yao Y, Zhou H, Shen S, et al. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes. Nat Commun. 2021;12:2623 pubmed publisher
Wang C, Wang S, Chen Y, Zhao J, Han S, Zhao G, et al. Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection. ACS Nano. 2021;15:6340-6351 pubmed publisher
Bertoglio F, Meier D, Langreder N, Steinke S, Rand U, Simonelli L, et al. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface. Nat Commun. 2021;12:1577 pubmed publisher
Piepenbrink M, Park J, Oladunni F, Deshpande A, Basu M, Sarkar S, et al. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Rep Med. 2021;2:100218 pubmed publisher
Daniloski Z, Jordan T, Ilmain J, Guo X, Bhabha G, tenOever B, et al. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. elife. 2021;10: pubmed publisher
image
image 1 :
Sino Biological 40591-V08H3 image 1
product information
Catalog Number :
40591-V08H3
Product Name :
SARS-CoV-2 (2019-nCoV) Spike S1(D614G)-His Recombinant Protein, (HPLC-verified)
Product Type :
Protein
Host Species :
HEK293 Cells
Conjugation :
C-His
Size :
100 µg
List Price :
498 USD
Gene ID :
YP_009724390.1
Product Description :
A DNA sequence encoding the SARS-CoV-2 (2019-nCoV) Spike S1(D614G)-His Recombinant Protein (YP_009724390.1) (Val16-Arg685(D614G)) was expressed with a polyhistidine tag at the C-terminus.
SpeciesSummary :
SARS-CoV-2
ALTnames :
Spike
Purity :
> 90 % as determined by SDS-PAGE. > 90 % as determined by SEC-HPLC.
Buffer :
Lyophilized from sterile PBS,pH 7.4
Packaging :
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature. Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Storage :
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
more info or order :
Sino Biological product webpage
company information
Sino Biological
Building 9, No.18 Kechuang 10th St, BDA, Beijing, 100176
marketing@sinobiological.com
https://www.sinobiological.com
86 400-890-9989
headquarters: China
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offer pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates.